ALISO VIEJO, Calif.--(BUSINESS WIRE)--Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the Company’s CEO, Ron A. Andrews, has issued a corporate update to shareholders:
